- Clinical Trials
- April 2025
- 60 Pages
Global
From €1103EUR$1,250USD£961GBP
- Report
- January 2026
- 506 Pages
Global
From €5162EUR$5,850USD£4,496GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1765EUR$2,000USD£1,537GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1103EUR$1,250USD£961GBP
- Report
- January 2025
- 175 Pages
Global
From €3962EUR$4,490USD£3,451GBP
- Report
- May 2024
- 134 Pages
Global
From €5734EUR$6,499USD£4,995GBP
- Report
- December 2022
- 42 Pages
Global
From €3088EUR$3,500USD£2,690GBP
- Report
- October 2022
- 69 Pages
Global
From €3088EUR$3,500USD£2,690GBP
- Report
- October 2022
- 41 Pages
Global
From €3088EUR$3,500USD£2,690GBP
- Report
- August 2024
- 78 Pages
Global
From €3500EUR$4,249USD£3,155GBP
- Report
- November 2021
- 844 Pages
Global
From €4412EUR$5,000USD£3,843GBP
The Metabotropic Glutamate Receptor (mGluR) market is a subset of the Central Nervous System (CNS) drugs market. mGluRs are a class of G-protein coupled receptors that are involved in a variety of physiological processes, including learning and memory, pain perception, and anxiety. mGluRs are also implicated in a number of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and schizophrenia. As such, mGluR-targeted drugs are being developed to treat these conditions.
The mGluR market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms developing mGluR-targeted drugs. Companies such as Merck, Pfizer, Novartis, and Eli Lilly are actively researching and developing mGluR-targeted drugs. Additionally, a number of smaller biotechnology firms, such as Neurocrine Biosciences, ACADIA Pharmaceuticals, and Ovid Therapeutics, are also developing mGluR-targeted drugs. Show Less Read more
